Scott N. Gettinger
656 works · 64,085 citations · h-index 83
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Programmed death ligand-1 expression in non-small cell lung cancer
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021